<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201003048912N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-02-20</date_registration>
      <primary_sponsor>Avicenna University Jihad Infertility Center Avicenna</primary_sponsor>
      <public_title>Effect of Growth Hormone on Improve Pregnancy Rate in Women with poor ovarian response</public_title>
      <acronym></acronym>
      <scientific_title>Effect of Growth Hormone on Improve Pregnancy Rate in Women with poor ovarian response</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>124</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53763</url>
      <study_type>observational</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The s ampling method was convenient and the samples were randomly assigned to two groups of received Growth Hormone counseling (intervention) and non-received Growth Hormone counseling (control) by four-sized randomized blocks. There were six possibiliti es for inclusion in blocks (BABA, BBAA, ABBA, AABB, ABAB and BAAB). At the beginning of study, one of blocks was selected and four participants were put in that block, so that the number A belonged to the intervention group (GH), and number B to the control group (Non GH). The details of blocks were contained in asset of sealed envelopes; the person that did allocation did not have any information about research. random numbers form with the help of computers. If the number is between 1 and 6.1, block 1. If it is between 6.2 and 12, block 2 and continue this way  up to 30.1-36.2 to be in block 6, Blinding description: The researchers responsible for data collection and those who assess outcomes will not have access to patients’ medical records and clinical report forms. They will simply collect patients’ outcomes based on the initial list for participation in the research. These people will not be aware of the type of assignment of participants to the control and intervention group.</study_design>
      <phase>3</phase>
      <hc_freetext>Patients with poor ovarian response.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients will receive 4 units of subcutaneous growth hormone of Sinagen Company from the 21st day of menstruation, one month before the start of cycle to the day of trigger hug injection. From the third day of menstruation, the patient will receive a gonadotropin injection and an antagonist protocol according to the routine of Ibn Sina Infertility Center, and it continues until the day of the growth hormone trigger injection; 36 hours after trigger injection, they will be punctured and according to endometrial conditions, they will routinely be undergone frozen or fresh embryo transfer. Intervention 2: Control group: Patients without receiving growth hormone from the third day of menstruation receive gonadotropin injection and antagonist protocol according to the routine of Ibn Sina Infertility Center and it continues until the day of growth hormone trigger injection; 36 hours after trigger injection, they are punctured and according to endometrial conditions, they are routinely undergone to frozen or fresh embryo transfer.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Effect of Growth Hormone on Improve Pregnancy Rate in Women with poor ovarian response

When:
Up to one year after the publication of the article

To whom:
Access to the effect of chemical and clinical pregnancy rates after receiving growth hormone will be available to other researchers and physicians in coordination with the principal investigator.

Conditions:
Using in meta-analysis studies

Where to obtain:
Marzdaran Town, Isar St., Motamedi St., Sahel Alley, No. 2 Avicenna University Jihad Infertility Center Dr. Mina Ataei Tell: 00982122432020

How to obtain:
Email to corresponding author Dr Mina Ataei Ataee.mina@yahoo.com

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Mina Ataei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Marzdaran Town, Isar St., Motamedi St., Sahel Alley, No. 2</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1941913114</zip>
        <telephone>+98 21 2243 2020</telephone>
        <email>Atlee.mina@yahoo.com</email>
        <affiliation>Avicenna University Jihad Infertility Center</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mina Ataei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Marzdaran Town, Isar St., Motamedi St., Sahel Alley, No. 2</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1941913114</zip>
        <telephone>+98 21 2243 2020</telephone>
        <email>Atlee.mina@yahoo.com</email>
        <affiliation>Avicenna University Jihad Infertility Center</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age less than 40 years,
Normal karyotype,
Normal thrombophilia (having two or less than two positive tests for thrombophilic heterozygotes)
Formation of 5 embryos (more than 3 embryos with good quality)
Patients with poor ovarian response (history of an ovulation stimulation cycle with less than 4 oocytes and AMH &lt;1.1 and FSH &lt;20) in infertile women referred to Ibn Sina Infertility Treatment Center</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Endometriosis disease
Severe oligospermia (morphology count &lt;1%)
Patients with hydrosalpinx
History of ovarian surgery
Underlying disease such as kidney and liver and diabetes and thyroid autoimmune
Allergic local reactions and benign increase in intracranial pressure</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N97</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Female infertility</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients will receive 4 units of subcutaneous growth hormone of Sinagen Company from the 21st day of menstruation, one month before the start of cycle to the day of trigger hug injection. From the third day of menstruation, the patient will receive a gonadotropin injection and an antagonist protocol according to the routine of Ibn Sina Infertility Center, and it continues until the day of the growth hormone trigger injection; 36 hours after trigger injection, they will be punctured and according to endometrial conditions, they will routinely be undergone frozen or fresh embryo transfer.</i_keyword>
      <i_keyword>Control group: Patients without receiving growth hormone from the third day of menstruation receive gonadotropin injection and antagonist protocol according to the routine of Ibn Sina Infertility Center and it continues until the day of growth hormone trigger injection; 36 hours after trigger injection, they are punctured and according to endometrial conditions, they are routinely undergone to frozen or fresh embryo transfer.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pregnancy rate. Timepoint: Three months after taking the drug. Method of measurement: The number of patients with BHCG positive is divided by the number of patients who had fetus transfer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Avicenna University Jihad Infertility Center Avicenna</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-10-06</approval_date>
        <contact_name>University Jihad Avicenna Infertility Center</contact_name>
        <contact_address>Tehran, Shariati St., corner of Yakhchal St., No. 97, Jihad University Avicenna Infertility Center Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
